{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:38:00Z","timestamp":1791185880957,"version":"4.1.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T00:00:00Z","timestamp":1398988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0096209","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T20:28:10Z","timestamp":1399062490000},"page":"e96209","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis"],"prefix":"10.1371","volume":"9","author":[{"given":"Serena","family":"De Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka K.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Gavillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gerbaulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Roers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"BJ Longley","year":"1996","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"HP Horny","year":"2001","journal-title":"Leuk Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"P Valent","year":"2001","journal-title":"Leuk Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"H Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"AC Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Y Ma","year":"2002","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"C Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"NP Shah","year":"2006","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"S Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, <etal>et al<\/etal>.KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. Blood (Annual Meeting Abstracts). November 2012 (120: 799.).","DOI":"10.1182\/blood.V120.21.799.799"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"A Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"F Traina","year":"2012","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"TM Wilson","year":"2011","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","article-title":"Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine","volume":"333","author":"S Ito","year":"2011","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.1210944","article-title":"Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA","volume":"333","author":"YF He","year":"2011","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"F Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"A Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"SM Langemeijer","year":"2009","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"K Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"C Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Z Li","year":"2011","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"E Soucie","year":"2012","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2008-11-189605","article-title":"Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit","volume":"117","author":"A Gerbaulet","year":"2011","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.7660125","article-title":"Inducible gene targeting in mice","volume":"269","author":"R Kuhn","year":"1995","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11248-007-9153-4","article-title":"Mast cell-specific Cre\/loxP-mediated recombination in vivo","volume":"17","author":"J Scholten","year":"2008","journal-title":"Transgenic Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/BF00481442","article-title":"Mast cell pharyngitis as a cause of supraglottic edema","volume":"245","author":"JH Butterfield","year":"1988","journal-title":"Arch Otorhinolaryngol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"KJ Aichberger","year":"2009","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"AS Yavuz","year":"2002","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.1073\/pnas.0504197102","article-title":"Identification of mast cell progenitors in adult mice","volume":"102","author":"CC Chen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0509148102","article-title":"Developmental checkpoints of the basophil\/mast cell lineages in adult murine hematopoiesis","volume":"102","author":"Y Arinobu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4049\/jimmunol.131.1.282","article-title":"Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity","volume":"131","author":"JN Ihle","year":"1983","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4049\/jimmunol.132.3.1479","article-title":"Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan","volume":"132","author":"E Razin","year":"1984","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"MM Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"ME Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders","volume":"62","author":"WD Travis","year":"1988","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"A Pardanani","year":"2009","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"HP Horny","year":"2004","journal-title":"J Clin Pathol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/pbc.21640","article-title":"Acute lymphoblastic leukemia and cutaneous mastocytosis in two children","volume":"51","author":"C Masserot","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"ref39","first-page":"530P","article-title":"Urticaria pigmentosa and acute lymphoblastic leukaemia","volume":"88","author":"HM Lewis","year":"1995","journal-title":"J R Soc Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V88.3.995.995","article-title":"Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase","volume":"88","author":"H Kitayama","year":"1996","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/MCB.01153-06","article-title":"Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling","volume":"27","author":"Z Xiang","year":"2007","journal-title":"Mol Cell Biol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/leu.2010.243","article-title":"TET2 mutations in childhood leukemia","volume":"25","author":"SM Langemeijer","year":"2011","journal-title":"Leukemia"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Estey EH (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia.","DOI":"10.1038\/leu.2013.173"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-09-382770","article-title":"5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand","volume":"119","author":"V Ghanim","year":"2012","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"HC Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2012-09-459313","article-title":"Genomic impact of transient low-dose decitabine treatment on primary AML cells","volume":"121","author":"JM Klco","year":"2013","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0096209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:24:33Z","timestamp":1689179073000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0096209"}},"subtitle":[],"editor":[{"given":"Halvard","family":"Boenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,2]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0096209","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,2]]}}}